LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock Holdings Lifted by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 45.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 147,489 shares of the medical instruments supplier's stock after acquiring an additional 46,430 shares during the quarter. JPMorgan Chase & Co. owned 0.66% of LeMaitre Vascular worth $13,590,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Raymond James Financial Inc. acquired a new position in shares of LeMaitre Vascular in the 4th quarter valued at about $14,900,000. Segall Bryant & Hamill LLC purchased a new position in LeMaitre Vascular during the fourth quarter worth about $5,446,000. Barclays PLC lifted its holdings in LeMaitre Vascular by 394.5% during the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock worth $3,396,000 after acquiring an additional 29,180 shares during the period. State Street Corp boosted its holdings in shares of LeMaitre Vascular by 3.6% in the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier's stock worth $76,363,000 after buying an additional 28,525 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its position in shares of LeMaitre Vascular by 31.8% during the 4th quarter. Teacher Retirement System of Texas now owns 101,851 shares of the medical instruments supplier's stock valued at $9,385,000 after acquiring an additional 24,586 shares during the period. Institutional investors own 84.64% of the company's stock.

Insiders Place Their Bets

In other news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company's stock, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.79% of the stock is owned by corporate insiders.

Remove Ads

LeMaitre Vascular Trading Up 1.0 %

LMAT stock traded up $0.85 during midday trading on Tuesday, reaching $84.63. The stock had a trading volume of 145,216 shares, compared to its average volume of 159,288. The company has a market cap of $1.91 billion, a price-to-earnings ratio of 46.25, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. The company's fifty day simple moving average is $88.88 and its 200 day simple moving average is $93.68. LeMaitre Vascular, Inc. has a 52-week low of $62.39 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.49. The firm had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. Sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.95%. This is a boost from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date of this dividend was Thursday, March 13th. LeMaitre Vascular's dividend payout ratio (DPR) is 41.24%.

Analysts Set New Price Targets

Several research analysts recently commented on LMAT shares. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price objective for the company. Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Lake Street Capital raised their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Finally, Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $95.25.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.